Spine BioPharma
Spine BioPharma is a privately held clinical-stage biopharmaceutical company developing SB-01, a TGFβ1-modulating peptide injection intended as a non-opioid, non-surgical treatment for chronic low back pain caused by degenerative disc disease.
- Company typePrivate
- Founded2015
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Spine BioPharma does
Spine BioPharma's business model is that of a clinical-stage biotech: it generates no commercial revenue, monetizes value through equity and convertible debt financings rather than product sales, and intends to serve chronic low back pain patients with degenerative disc disease once (and if) SB-01 receives regulatory approval. The company has raised roughly $50 million in cumulative disclosed funding across multiple rounds since at least 2021, with named investors including Viscogliosi Brothers (lead investor in 2021), Cercano Management, Pacira Pharmaceuticals, and Vulcan Capital. Leadership is concentrated around Marc R. Viscogliosi as Chairman & CEO. Pricing, go-to-market, distribution, and reimbursement mechanics are not publicly disclosed because the company has no approved or commercialized product; near-term value creation depends on clinical re-strategy, partnership, or a pipeline expansion following the Phase III failure.
Spine BioPharma firmographics
Firmographics- Name
- Spine BioPharma
- Legal name
- Spine BioPharma, Inc.
- Website
- https://spinebiopharma.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Spine BioPharma is a privately held clinical-stage biopharmaceutical company developing SB-01, a TGFβ1-modulating peptide injection intended as a non-opioid, non-surgical treatment for chronic low back pain caused by degenerative disc disease.
- Ownership category
- akta.pro rank
Spine BioPharma industry classification
Industry- Product category
- Biopharmaceutical peptide therapeutics for spinal disorders
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
- akta.pro secondary industry
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
Keywords
Where Spine BioPharma is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Spine BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Spine BioPharma product offering
Product offeringCore offering
Spine BioPharma develops SB-01 for injection, a peptide therapeutic designed to treat degenerative disc disease by modulating TGFβ1 to reduce inflammation and support disc health. The product is being advanced as a non-opiate, non-surgical treatment alternative for chronic low back pain associated with degenerative disc disease. The company's pipeline is centered on SB-01, which it has taken through Phase III clinical development (the MODEL trial).
Product overview
Spine BioPharma is a biopharmaceutical company developing a single therapeutic candidate, SB-01 for injection. SB-01 is a peptide-based drug designed to treat degenerative disc disease by modulating TGFβ1 to reduce inflammation and support disc health, targeting chronic low back pain patients seeking non-opiate, non-surgical treatment options. The company's primary pipeline activity is advancing SB-01 through clinical development, having completed a Phase III MODEL trial.
Differentiator
Problem solved
Functional benefit
Products and services
- SB-01 for injection SB-01 for injection is a peptide therapeutic designed to treat degenerative disc disease by modulating TGFβ1 to reduce inflammation and support disc health. It is being developed as a non-opiate, non-surgical treatment for chronic low back pain associated with degenerative disc disease, targeting patients who would otherwise rely on opioids or surgical interventions.
Quantifiable outcome
- Phase III MODEL trial did not meet primary endpoint for SB-01 in chronic low back pain
Companies that use Spine BioPharma
Customer profileSegments1 record
Ideal customer profiles1 record
Spine BioPharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Spine BioPharma partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights3 records
Spine BioPharma competitors and assessment
Company assessmentDirect peers
- Kolon TissueGene: Develops TG-C, an allogeneic cell-based therapy for degenerative disc disease that has advanced through late-stage clinical trials — a direct competitor in the same indication using a related regenerative approach.
- Mesoblast: Commercial-stage cellular medicines company that has run late-stage clinical trials of MPC-06-ID for chronic low back pain due to degenerative disc disease — directly competitive in indication, mechanism class, and clinical stage.
- DiscGenics: Clinical-stage regenerative medicine company developing IDCT (rebonupatamagene autotemcel), a cell therapy for degenerative disc disease — the most directly comparable asset and indication to SB-01.
- Seikagaku Corporation: Japanese specialty pharma with marketed joint-preservation products (hyaluronic acid, disc-related injectables) and pipeline assets in MSK regeneration — overlapping with SB-01's MSK/peptide therapeutic space.
- Anika Therapeutics: Joint-preservation and regenerative medicine company with hyaluronic-acid-based therapies for osteoarthritis and adjacent MSK indications — overlapping therapeutic category and commercial channels.
- VIVEX Biologics: Specialty spine and orthopedics biologics company marketing amniotic membrane and tissue-based products for spine surgery and disc-related applications — comparable in spine therapeutic focus.
Broad incumbents
- Pacira BioSciences: Specialty pharmaceutical company commercializing non-opioid pain therapeutics (e.g., EXPAREL) and a strategic investor in Spine BioPharma. Comparable as a broad incumbent in non-opioid pain and as a strategic stakeholder in the asset.
- Scilex Holding: Commercial-stage non-opioid pain management company controlled by the Viscogliosi Brothers. Compares as a related-party incumbent in the same non-opioid pain therapeutic space and through overlapping leadership/ownership.
- Sorrento Therapeutics: Diversified biopharma with pain management assets (including non-opioid injectables) — broader incumbent operating in the same pain therapeutics category that SB-01 targets.
Emerging players
- BioRestorative Therapies: Early-stage stem cell therapy developer with programs targeting disc and spine-related conditions; partial overlap in mechanism and indication with SB-01.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Spine BioPharma social profiles
Digital presenceSpine BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spine BioPharma leadership team
Management profileNumber of profiles
Profiles1 record
Spine BioPharma funding detail
Funding detailFunding overview
Funding rounds12 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spine BioPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spine BioPharma
What does Spine BioPharma do?
Spine BioPharma develops SB-01 for injection, a peptide therapeutic designed to treat degenerative disc disease by modulating TGFβ1 to reduce inflammation and support disc health. The product is being advanced as a non-opiate, non-surgical treatment alternative for chronic low back pain associated with degenerative disc disease. The company's pipeline is centered on SB-01, which it has taken through Phase III clinical development (the MODEL trial).
Is Spine BioPharma a public or private company?
Spine BioPharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Spine BioPharma founded?
Spine BioPharma was founded in 2015. It employs 11 to 50 people.
Where is Spine BioPharma based?
Spine BioPharma is headquartered in New York, United States, in the North America region.
Who are Spine BioPharma's main competitors?
Direct peers on record are Kolon TissueGene, Mesoblast, DiscGenics, Seikagaku Corporation, Anika Therapeutics and VIVEX Biologics. Broad incumbents are Pacira BioSciences, Scilex Holding and Sorrento Therapeutics. BioRestorative Therapies is listed as an emerging player.
Does Spine BioPharma have an API?
No public API is recorded for Spine BioPharma.
What industry is Spine BioPharma in?
Spine BioPharma's product category is Biopharmaceutical peptide therapeutics for spinal disorders. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.